PMID: 18325607DOI: 10.1016/j.antiviral.2008.01.008Mar 8, 2008Paper

Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.

Antiviral Research
Alistair McGregorMark R Schleiss

Abstract

In lieu of a licensed vaccine, antivirals are being considered as an intervention to prevent congenital human cytomegalovirus (HCMV) infection. Ideally, antiviral therapies should undergo pre-clinical evaluation in an animal model prior to human use. Guinea pig cytomegalovirus (GPCMV) is the only small animal model for congenital CMV. However, GPCMV is not susceptible to the most commonly used HCMV antiviral, ganciclovir (GCV), rendering in vivo study of this agent problematic in the guinea pig model. Human cytomegalovirus (HCMV) susceptibility to GCV is linked to the UL97 gene. We hypothesized that GPCMV susceptibility to GCV could be improved by inserting the HCMV (Towne) UL97 gene into the GPCMV genome in place of the homolog, GP97. A chimeric GPCMV (GPCMV::UL97) expressed UL97 protein, and replicated efficiently in cell culture, with kinetics similar to wild-type GPCMV. In contrast, deletion of GP97 resulted in a virus (GPCMVdGP97) that grew poorly in culture. GPCMV::UL97 had substantially improved susceptibility to the inhibitory effects of GCV in comparison to wild-type GPCMV. Additionally, GPCMV::UL97 exhibited improved susceptibility to another antiviral undergoing clinical trials, maribavir (MBV; benzimidazole riboside...Continue Reading

References

Experimental congenital infection with cytomegalovirus: a guinea pig model

Nov 1, 1978·The Journal of Infectious Diseases·M L Kumar, G A Nankervis

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Sep 3, 1992·Nature·V SullivanK K Biron

Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis.

Jun 1, 1988·Antimicrobial Agents and Chemotherapy·N K WoolfD D Richman

Antiviral activity and mechanism of action of ganciclovir

Jul 1, 1988·Reviews of Infectious Diseases·T Matthews, R Boehme

Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model

Jan 1, 1987·Antiviral Research·C K FongG D Hsiung

Cytomegaloviral infections in the guinea pig: experimental models for human disease

Mar 1, 1983·Reviews of Infectious Diseases·F J BiaG D Hsiung

Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates

Jul 1, 1995·The Journal of Infectious Diseases·S ChouW L Drew

Partial substitution of the functions of the herpes simplex virus 1 U(L)13 gene by the human cytomegalovirus U(L)97 gene

Nov 15, 1996·Virology·T I NgB Roizman

The murine cytomegalovirus (MCMV) homolog of the HCMV phosphotransferase (UL97(pk)) gene

Jul 7, 1997·Virology·W D RawlinsonG M Scott

Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself

Sep 25, 1998·The Journal of General Virology·D MichelT Mertens

Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals

Sep 21, 2000·Antiviral Research·N BourneD I Bernstein

Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity

Oct 24, 2000·Journal of Virology·M WagnerU Koszinowski

Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli

Feb 13, 2001·Molecular Genetics and Metabolism·A McGregor, M R Schleiss

Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation

Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·D G WolfE S Mocarski

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Jul 18, 2002·Antimicrobial Agents and Chemotherapy·Karen K BironGeorge W Koszalka

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

Jun 25, 2003·Antimicrobial Agents and Chemotherapy·Stephanie L WilliamsEarl R Kern

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

Aug 14, 2003·The Journal of Pediatrics·David W KimberlinUNKNOWN National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

Cutaneous vascular malformation in a guinea pig (Cavia porcellus)

Mar 3, 2004·Veterinary Dermatology·Anna OsofskyStephen D White

The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host

Mar 17, 2004·Biochimica Et Biophysica Acta·Detlef Michel, Thomas Mertens

Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone

Mar 26, 2004·Virus Research·Alistair McGregorMark R Schleiss

Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs

Jun 3, 2004·Human Immunology·Fausto BaldantiGiuseppe Gerna

Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83)

Aug 28, 2004·Journal of Virology·Alistair McGregorMark R Schleiss

The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs

Jan 18, 2005·Antiviral Research·Mark R SchleissSabine Hallenberger

Human cytomegalovirus resistance to antiviral drugs

Feb 25, 2005·Antimicrobial Agents and Chemotherapy·C Gilbert, G Boivin

Passive immunization during pregnancy for congenital cytomegalovirus infection

Sep 30, 2005·The New England Journal of Medicine·Giovanni NigroUNKNOWN Congenital Cytomegalovirus Collaborating Group

Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis

Nov 25, 2005·Journal of Virology·Mark N PrichardEarl R Kern

Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection

Jan 21, 2006·The Journal of Infectious Diseases·Fernando J BravoDavid I Bernstein

The effect of cidofovir on cytomegalovirus-induced hearing loss in a Guinea pig model

Jun 21, 2006·Archives of Otolaryngology--head & Neck Surgery·David R WhiteMark R Schleiss

Pivotal role of animal models in the development of new therapies for cytomegalovirus infections

Jul 11, 2006·Antiviral Research·Earl R Kern

Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity

Jul 29, 2006·Virology·Maysa AzzehDana G Wolf

Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine

Aug 2, 2006·Vaccine·Mark R SchleissAlistair McGregor

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

Sep 12, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·W Lawrence DrewSunwen Chou

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus

Sep 29, 2006·Antimicrobial Agents and Chemotherapy·Sunwen Chou, Gail I Marousek

Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation

Nov 28, 2006·Journal of Medicinal Chemistry·Daniel RomakerManfred Marschall

Animal models of human placentation--a review

Jan 2, 2007·Placenta·A M Carter

The Guinea pig placenta: model of placental growth dynamics

Mar 27, 2007·Placenta·A Mess

❮ Previous
Next ❯

Citations

Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Feb 14, 2014·Future Virology·Mark R Schleiss

Cytomegalovirus antivirals and development of improved animal models.

Sep 3, 2011·Expert Opinion on Drug Metabolism & Toxicology·Alistair McGregor, K Yeon Choi

Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV

Nov 26, 2010·Virology·A McGregorM R Schleiss

Viral Glycoprotein Complex Formation, Essential Function and Immunogenicity in the Guinea Pig Model for Cytomegalovirus

Aug 13, 2015·PloS One·Stewart ColemanAlistair McGregor

A Homolog Pentameric Complex Dictates Viral Epithelial Tropism, Pathogenicity and Congenital Infection Rate in Guinea Pig Cytomegalovirus

Jul 9, 2016·PLoS Pathogens·Stewart ColemanAlistair McGregor

Guinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission

Mar 1, 2010·Future Virology·Mark R Schleiss, Michael A McVoy

A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection

Jun 24, 2016·Journal of Virology·K Yeon ChoiAlistair McGregor

Guinea pig cytomegalovirus protective T cell antigen GP83 is a functional pp65 homolog for innate immune evasion and pentamer dependent virus tropism.

Mar 5, 2021·Journal of Virology·K Yeon ChoiAlistair McGregor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Artificial Chromosomes

Artificial chromosomes are genetically engineered chromosomes derived from the DNA of a species. Discover the latest research on artificial chromosomes here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Related Papers

ContactHelpTerms Privacy Cookies
© 2022 Meta ULC. All rights reserved